Prescribing a Sedative Antidepressant for Patients at Work or on Sick Leave under Conditions of Routine Care

Abstract

Background: Sedation can be a beneficial effect of medication, but it can also be an unwanted side-effect, especially in patients who have to work. The aim of this study is to analyze whether physicians prescribe sedative antidepressants differently for patients at work vs. those on sick leave.

Methods: A drug utilization study of mirtazapine was conducted for 12 weeks on 594 depressed outpatients from 227 general practitioners or psychiatrists. There were 319 patients working and 275 patients on sick leave. The two groups were compared regarding sociodemographic variables, illness characteristics, mode and course of treatment.

Results: As expected, patients on sick leave were sicker than working patients; they were treated by specialists more often and received higher dosages of mirtazapine. Work status had no influence on dosage after controlling for severity of illness, patient sex, and physician specialty. The overall improvement of depression was similar in both patient groups. Under treatment with mirtazapine, 64.5% of patients on sick leave returned to work, while 2.6% of the patients initially at work went on sick leave by the end of the 12 weeks. Sedation as an undesired side-effect was reported in less than 1%. The rate of sedative polypharmacy declined during treatment with mirtazapine.

Conclusion: The results suggest that in routine treatment physicians do not see a need to adjust prescribing of mirtazapine because of its sedative properties to the working status of the patients. The majority of patients on sick leave returned to work. Mirtazapine can help to reduce sedative polypharmacy.

References

• 1 Adler DA, Irish J, McLaughlin TJ. et al . The work impact of dysthymia in a primary care population.  Gen Hosp Psychiatry. 2004;  26 269-275
• 2 Adler DA, McLaughlin TJ, Rogers WH. et al . Job performance deficits due to depression.  Am J Psychiatry. 2006;  163 1569-1576
• 3 American Psychiatric Association . Practice guidelines for the treatment of patients with major depressive disorders (revision).  Am J Psychiatry. 2000;  157 1-45
• 4 Aslan S, Isik E, Cosar B. The effect of mirtazapine on sleep: A placebo controlled, double-blind study in young healthy volunteers.  Sleep. 2000;  25 666-668
• 5 Benkert O, Szegedi A, Philipp M. et al . Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.  J Clin Psychopharmacol. 2006;  26 75-78
• 6 Biswas PN, Wilton LV, Shakir SAW. The pharmacovigilance of mirtazapine: results of the prescription event monitoring study on 13 554 patients in England.  J Psychopharmacology. 2003;  17 121-126
• 7 Brunnauer A, Laux G, Geiger E. et al . Antidepressants and driving ability: Results from a clinical study.  J Clin Psychiatry. 2006;  67 1776-1781
• 8 Degner D, Grohman R, Kropp S. et al . Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.  Pharmacopsychiatry. 2004;  37 S39-S45
• 9 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) . Praxisleitlinien für Psychiatrie und Psychotherapie.  Kurzversion der Behandlungsleitlinie “Affektive Erkrankungen” [DGPPN Web site]. 2006;  Available at  http://www.dgppn.de/leitlinien/pdf/leitliniebd5affektiveerkrankungen.pdf Accessed January, 26, 2008 
• 10 Du Y, Scheidt-Nave C, Knopf H. Use of psychotropic drugs and alcohol among non-institutionalised elderly adults in Germany.  Pharmacopsychiatry. 2008;  41 242-251
• 11 Elinson L, Houck P, Marcus SC. et al . Depression and the ability to work.  Psychiatr Serv. 2004;  55 29-34
• 12 Falkai P. Mirtazapine: other indications.  J Clin Psychiatry. 1999;  60 36-40
• 13 Fava M. Daytime sleepiness and insomnia as correlates of depression.  J Clin Psychiatry. 2004;  65 27-32
• 14 Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.  J Affect Disord. 1998;  51 167-185
• 15 Furukawa TA, Streiner DL, Young T. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study.  J Affect Disord. 2001;  65 173-177
• 16 Goodnick PJ, Puig A, DeVane CL. et al . Mirtazapine in major depression with comorbid generalized anxiety disorder.  J Clin Psychiatry. 1999;  60 446-448
• 17 Greener MJ, Guest JF. Do antidepressants reduce the burden imposed by depressions on employers?.  CNS Drugs. 2005;  19 253-264
• 18 Hartmann PM. Mirtazapine: a newer antidepressant.  Am Fam Physician. 1999;  59 159-161
• 19 Hendset M, Haslemo T, Rudberg I. et al . The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.  Pharmacopsychiatry. 2006;  39 121-127
• 20 Lam RW. Sleep disturbance and depression: a challenge for antidepressants.  Int Clin Psychopharmacol. 2006;  21 25-29
• 21 Lange K, Geisler P, Klein HE. et al . Sedierende Antidepressiva in der Behandlung von Patienten mit primärer Insomnie.  Psychopharmakotherapie. 2007;  34 95-97
• 22 Lerner D, Adler DA, Chang H. et al . The clinical and occupational correlates of work productivity loss among employed patients with depression.  J Occup Environ Med. 2004;  46 46-55
• 23 Lerner D, Adler DA, Chang H. et al . Unemployment, job retention, and productivity loss among employees with depression.  Psychiatr Serv. 2004;  55 1371-1378
• 24 Linden M, Schotte K. A randomized controlled clinical trial comparing “guideline exposed” and “guideline naïve” physicians in respect to dosage selection and treatment outcome with doexepin with depressive disorders.  Pharmacopsychiatry. 2007;  40 77-81
• 25 Linden M, Weidner C. Arbeitsunfähigkeit bei psychischen Störungen.  Der Nervenarzt. 2005;  76 1421-1431
• 26 Lo Sasso AT, Rost K, Beck A. Modeling the impact of enhanced depression treamtent on workplace functioning and costs.  A cost-benefit approach. Medical Care. 2006;  44 352-358
• 27 Mayers AG, Baldwin DS. Antidepressants and their effect on sleep.  Hum Psychopharmacol Clin Exp. 2005;  20 533-559
• 28 Montgomery SA, Baldwin SB, Blier P. et al . Which antidepressants have demonstrated superior efficacy? A review of the evidence.  Int Clin Psychopharmacol. 2007;  22 323-329
• 29 National Institute of Mental Health (NIMH) .Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment in Psychopharmacology. Rev. Ed. Rockville, Maryland p 217-222
• 30 Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine.  Ann Epidemiol. 1995;  5 239-244
• 31 Radhakishun FS, van den Bos J, van der Heijden BC. et al . Mirtazapine on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.  J Clin Psychopharmacol. 2000;  20 531-537
• 32 Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.  J Clin Psychiatry. 2003;  64 20-29
• 33 Schotte K, Linden M. Correlates of low-dosage treatment with antidepressants by psychiatrists and general practitioners.  Pharmacoepidemiol Drug Saf. 2007;  16 675-680
• 34 Sonntag A, Matschinger H, Angermeyer MC. et al . Does the context matter? Utilization of sedative drugs in nursing homes – A multilevel analysis.  Pharmacopsychiatry. 2006;  39 142-149
• 35 Thase ME. Treatment issues related to sleep and depression.  J Clin Psychiatry. 2000;  61 46-50
• 36 Timmer CJ, Sitsen AJM, Delbressine LP. Clinical pharmacokinetics of mirtazapine.  Clin Pharmacokinet. 2000;  38 461-474
• 37 U.   S. Food and Drug Administration . Mirtazapine (marketed as Remeron) Information [U. S. FDA Web site]. May 2007;  Available at  http://www.fda.gov/cder/drug/infosheets/patient/mirtazapinepis.pdf Accessed January, 26, 2008 
• 38 Valenstein M, Taylor KK, Austin K. et al . Benzodiazepine use among patients treated in mental health settings.  Am J Psychiatry. 2004;  161 654-661
• 39 WHO .Diagnostic and management guidelines for mental disorders in primary care: ICD- 10 Chapter V Primary care version. World Health Organization, Geneve 1996
• 40 WHO .International classification of functioning, disability and health. World Health Organization, Geneve 2001
• 41 Winokur A, Sateia MJ, Hayes JB. et al . Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.  Biol Psychiatry. 2000;  48 75-78

Correspondence